Actuate Therapeutics (NASDAQ:ACTU) Coverage Initiated at Craig Hallum
Analysts at Craig Hallum began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $21.00 price target on the stock. Craig Hallum’s target price points to a potential upside of 133.33% from the company’s previous […]
Analysts at Craig Hallum began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $21.00 price target on the stock. Craig Hallum’s target price points to a potential upside of 133.33% from the company’s previous […]
